Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Roivant Sciences Ltd. ROIV
$9.05
-$0 (-0.06%)
На 18:04, 12 мая 2023
+32.60%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
7102668930.00000000
-
week52high
10.00
-
week52low
2.52
-
Revenue
55286000
-
P/E TTM
-5
-
Beta
1.19970300
-
EPS
-1.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
26 июн 2023 г. в 12:30
Описание компании
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 16 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 29 июн 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| SVB Leerink | Outperform | 23 мая 2022 г. | |
| Cantor Fitzgerald | Overweight | 29 апр 2022 г. | |
| SVB Leerink | Outperform | Outperform | 15 ноя 2022 г. |
| Citigroup | Buy | Buy | 15 ноя 2022 г. |
| Citigroup | Buy | Buy | 05 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 19 дек 2022 г. |
| Goldman Sachs | Buy | Buy | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kumar Rakhi | D | 134340 | 1838 | 24 янв 2023 г. |
| Gline Matthew | D | 1109634 | 15594 | 24 янв 2023 г. |
| Venker Eric | D | 716372 | 13057 | 24 янв 2023 г. |
| Venker Eric | D | 729429 | 24037 | 05 янв 2023 г. |
| MOMTAZEE JAMES C | A | 59774 | 2447 | 03 янв 2023 г. |
| Oren Ilan | A | 60171 | 2010 | 03 янв 2023 г. |
| Venker Eric | D | 753466 | 95484 | 03 янв 2023 г. |
| Venker Eric | D | 848950 | 23761 | 30 дек 2022 г. |
| Venker Eric | D | 901647 | 16031 | 23 дек 2022 г. |
| Kumar Rakhi | D | 136178 | 1592 | 23 дек 2022 г. |
Новостная лента
Roivant Sciences: A Solid Year Of Progress And Good Prospects For 2023
Seeking Alpha
20 дек 2022 г. в 15:32
Roivant's differentiated approach to the drug development business has been hit and miss. The company's subsidiary Dermavant won a first approval this year for Vtama cream - indicated for plaque psoriasis.
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug
Zacks Investment Research
02 дек 2022 г. в 12:48
Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.
Roivant Sciences Ltd. (ROIV) Q2 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 13:54
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Jeffrey Kalmus - Head, Strategic Finance Matt Gline - CEO Conference Call Participants David Risinger - SVB Securities Brian Cheng - J.P.
Analysts Estimate Roivant Sciences Ltd. (ROIV) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
07 ноя 2022 г. в 11:19
Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Roivant Sciences Ltd. (ROIV) Soars 5.8: Is Further Upside Left in the Stock?
Zacks Investment Research
28 окт 2022 г. в 06:02
Roivant Sciences Ltd. (ROIV) was a big mover last session on higher-than-average trading volume.